These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 19563908)

  • 1. Immune escape mechanisms of intraocular tumors.
    Niederkorn JY
    Prog Retin Eye Res; 2009 Sep; 28(5):329-47. PubMed ID: 19563908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunology of intraocular tumors.
    Niederkorn JY; Wang S
    Ocul Immunol Inflamm; 2005 Feb; 13(1):105-10. PubMed ID: 15835077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism?
    Niederkorn JY
    Front Immunol; 2012; 3():148. PubMed ID: 22707951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of immune surveillance and immune privilege on formation of intraocular tumors.
    Chen PW; Ksander BR
    Chem Immunol Allergy; 2007; 92():276-289. PubMed ID: 17264503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of immune privilege on ocular tumor development.
    McKenna KC; Chen PW
    Ocul Immunol Inflamm; 2010 Apr; 18(2):80-90. PubMed ID: 20370332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
    Chen PW; Uno T; Ksander BR
    Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells.
    Repp AC; Mayhew ES; Apte S; Niederkorn JY
    J Immunol; 2000 Jul; 165(2):710-5. PubMed ID: 10878343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunological studies in intraocular tumors].
    Kotelianskiĭ EO
    Oftalmol Zh; 1982; 37(1):54-8. PubMed ID: 7043350
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunoregulation of intraocular tumours.
    Niederkorn JY
    Eye (Lond); 1997; 11 ( Pt 2)():249-54. PubMed ID: 9349421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of immunological techniques in the diagnosis and prognosis of ocular malignant melanoma.
    Cochran AJ; Foulds WS; Damato BE; Trope GE; Morrison L; Lee WR
    Br J Ophthalmol; 1985 Mar; 69(3):171-6. PubMed ID: 3884037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.
    Ligocki AJ; Brown JR; Niederkorn JY
    J Leukoc Biol; 2016 May; 99(5):735-47. PubMed ID: 26578649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of uveal melanoma.
    Bosch JJ
    Dev Ophthalmol; 2012; 49():137-149. PubMed ID: 22042018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
    Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel Adjuvant Therapy for Ocular Melanoma].
    Bosch JJ; Heindl LM
    Klin Monbl Augenheilkd; 2017 May; 234(5):670-673. PubMed ID: 28505674
    [No Abstract]   [Full Text] [Related]  

  • 16. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
    Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
    J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splenectomy promotes indirect elimination of intraocular tumors by CD8+ T cells that is associated with IFNγ- and Fas/FasL-dependent activation of intratumoral macrophages.
    Miller MR; Mandell JB; Beatty KM; Harvey SA; Rizzo MJ; Previte DM; Thorne SH; McKenna KC
    Cancer Immunol Res; 2014 Dec; 2(12):1175-85. PubMed ID: 25248763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of ocular melanoma with cutaneous melanoma antibodies.
    Bomanji J; Garner A; Prasad J; Albert DM; Hungerford JL; Granowska M; Britton KE
    Br J Ophthalmol; 1987 Sep; 71(9):647-50. PubMed ID: 3311140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune privilege to MHC-disparate tumor grafts in the anterior chamber of the eye. I. Quantitative analysis of intraocular tumor growth and the corresponding delayed hypersensitivity response.
    Ksander BR; Streilein JW
    Transplantation; 1989 Apr; 47(4):661-7. PubMed ID: 2523103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.